Ceftriaxon versus ampicillin therapy for purulent meningitis in adults

P. Narciso, P. De Mori, R. Giannuzzi

Research output: Contribution to journalArticlepeer-review


Ten adult patients suffering from purulent meningitis were randomly treated with Rocephin (active ingredient ceftriaxon) or ampicillin. All the pathogens were sensitive to the agents used. All the patients were cured. In the patients treated with Rocephin, the parameters of the ESR and the halving time of the number of CSF cells returned to normal sooner than in the patients treated with ampicillin. Two patients in each group were in coma: the median awakening time was shorter in those in the Rocephin group than in patients in the other group. The authors are of the opinion that Rocephin, administered in a dose of 22-50 mg/kg bodyweight twice daily, provides a good alternative to ampicillin because of its outstanding penetration into the CSF and its high level of antimicrobial activity. It is especially indicated when the pathogens involved are resistant to other standard agents.

Original languageEnglish
Pages (from-to)717-719
Number of pages3
JournalDrugs under Experimental and Clinical Research
Issue number10
Publication statusPublished - 1983

ASJC Scopus subject areas

  • Molecular Medicine


Dive into the research topics of 'Ceftriaxon versus ampicillin therapy for purulent meningitis in adults'. Together they form a unique fingerprint.

Cite this